Targeting Pancreatic Stellate Cells in Cancer

被引：115

作者：

Schnittert, Jonas ^{[1
]}

Bansal, Ruchi ^{[1
]}

Prakash, Jai ^{[1
,2
]}

机构：

[1] Univ Twente, Fac Sci & Technol, Dept Biomat Sci & Technol, Targeted Therapeut, Enschede, Netherlands

[2] ScarTec Therapeut BV, Enschede, Netherlands

来源：

TRENDS IN CANCER | 2019年 / 5卷 / 02期

基金：

瑞典研究理事会;

关键词：

DUCTAL ADENOCARCINOMA; SUPPRESSOR-CELLS; DISTINCT POPULATIONS; DRUG-DELIVERY; LINE THERAPY; MOUSE MODEL; TGF-BETA; STROMA; PROMOTES; GEMCITABINE;

D O I：

10.1016/j.trecan.2019.01.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic stellate cells (PSCs) are the major contributor to the aggressive, metastatic, and resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis with a 5-year survival rate of 8%. PSCs constitute more than 50% of the tumor stroma in PDAC, where they induce extensive desmoplasia by secreting abundant extracellular matrix (ECM) proteins. In addition, they establish dynamic crosstalk with cancer cells and other stromal cells, which collectively supports tumor progression via various inter-and intracellular pathways. These cellular interactions and associated pathways may reveal novel therapeutic opportunities against this unmet clinical problem. In this review article, we discuss the role of PSCs in inducing tumor progression, their crosstalk with other cells, and therapeutic strategies to target PSCs.

引用

页码：128 / 142

页数：15

共 120 条

[1] Paracrine Secretion of Transforming Growth Factor β by Ductal Cells Promotes Acinar-to-Ductal Metaplasia in Cultured Human Exocrine Pancreas Tissues [J].